This Article Full Text Full Text (PDF) Supplementary Data All Versions of this Article: 1078-0432.CCR-07-1866v1 14/3/668    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Lerner, I. Articles by Elkin, M. PubMed PubMed Citation Articles by Lerner, I. Articles by Elkin, M.

Function of Heparanase in Prostate Tumorigenesis: Potential for Therapy

Authors' Affiliations: ¹ Sharett Institute of Oncology and ² Department of Pathology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel and ³ Cancer and Vascular Biology Research Center, The Bruce Rappaport Faculty of Medicine, Haifa, Israel

Requests for reprints: Michael Elkin, Tumor Biology Research Unit, Department of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel. Phone: 972-2-6776782; Fax: 972-2-6422794; E-mail: melkin{at}hadassah.org.il.

Purpose: Heparanase is the predominant enzyme that cleaves heparan sulfate, the main polysaccharide in the extracellular matrix. Whereas the role of heparanase in sustaining the pathology of human cancer is well documented, its association with prostate carcinoma remains uncertain. Our research was undertaken to elucidate the significance of heparanase in prostate tumorigenesis and bone metastasis.

Experimental Design: We applied immunohistochemical analysis of tissue microarray, in vitro adhesion and invasion assays, as well as mouse models of intraosseous growth and spontaneous metastasis of prostate cancer, monitored by whole-body bioluminescent imaging. Electroporation-assisted administration of anti-heparanase small interfering RNA in vivo was applied as a therapeutic approach.

Results: We report a highly statistically significant (P < 0.0001) prevalence of heparanase overexpression in prostate carcinomas versus noncancerous tissue, as well as strong correlation between tumor grade and the extent of heparanase expression. We observed >5-fold increase in the metastatic potential of PC-3 prostate carcinoma cells engineered to overexpress heparanase. Notably, overexpression of a secreted form of the enzyme also led to a dramatic increase in intraosseous prostate tumor growth. Local in vivo silencing of heparanase resulted in a 4-fold inhibition of prostate tumor growth, representing the first successful application of anticancer therapy based on heparanase small interfering RNA and validating the potential of heparanase as a target for prostate cancer treatment.

Conclusions: Heparanase directly contributes to prostate tumor growth in bone and its ability to metastasize to distant organs. Thus, anti-heparanase strategy may become an important modality in the treatment of prostate cancer patients, particularly those with bone metastases.